Cynata Therapeutics (CYP) Q4 2025 TU earnings summary

Executive summary

• Advanced clinical pipeline with four assets targeting osteoarthritis, GVHD, diabetic foot ulcers, and kidney transplantation, all addressing significant unmet needs.

• Three major clinical trial readouts are expected within the financial year, targeting large markets with high unmet needs.

• Cymerus platform uses iPSC-derived MSCs, enabling scalable, consistent, and potent cell therapy products, overcoming limitations of donor-derived MSCs.

• Entered a period of significant momentum with three clinical trials advancing in high-value therapeutic areas.

• Major clinical milestones expected in the coming year, including readouts from kidney transplant, GVHD phase II, and osteoarthritis phase III trials.

Financial highlights

• Share price as of 4 August 2025 is A$0.17, with a market capitalization of approximately A$38 million.

• Closed the quarter with $5.049 million in cash; net operating cash outflows for the quarter were $3.454 million.

• Top 20 shareholders hold nearly 50% of shares; major holders include BioScience Managers, Fidelity, and Fujifilm.

• Cash runway extends to mid-2026, covering all major upcoming clinical readouts.

• Anticipated R&D Tax Incentive rebate of $1.25 million in the next few months.

Outlook and guidance

• Enrollment completion for GVHD phase II expected in the next few months, with primary results in the first half of next calendar year.

• Osteoarthritis phase III trial fully enrolled; final results anticipated between February and April 2026.

• Kidney transplantation trial cohort 1 results expected by Q4 2025.

• Strategy focuses on advancing multiple candidates in indications with high unmet medical need and leveraging partnerships for execution and market access.

• Positive osteoarthritis phase III results could support marketing approval in Australia, with a clear regulatory path confirmed by TGA.